O2h Ventures

Sunil Shah, CEO of o2h Ventures and co-founder of the o2h group, leads investment activities. Andy Morley, Chief Scientific Officer, also leads scientific evaluations for investments and provides strategic support across portfolio projects.

O2h Ventures is the investment fund arm of o2h group, which is organized into six symbiotic verticals. These include o2h discovery (a drug discovery services platform), o2h technology (custom software development), o2h therapeutics (newco co-curation and spin-outs), o2h co-work labs, and o2h community. The group structure allows the venture arm to co-create and co-invest alongside portfolio companies using in-house expertise.

O2h Ventures focuses on direct, early-stage equity investments in biotech therapeutics and related AI companies. It operates through a UK S/EIS fund structure designed to seed emerging life science and technology opportunities. The firm has not publicly disclosed any fund-of-fund commitments or secondary market activity.

Based on its stated strategy, o2h Ventures targets pre-seed and seed stage biotech therapeutics and AI-related opportunities. The wider group's therapeutics vertical focuses on co-curating 'unloved or novel pre-seed ideas' and spinning them out for later seed-stage funding, suggesting the venture arm engages from the very earliest stages of company formation.

Prior to founding o2h group, Sunil and Prashant Shah co-founded Oxygen Healthcare Ltd, a drug discovery company that was acquired by Piramal Enterprises Ltd. This exit provided the entrepreneurial track record and likely the capital foundation that led to the creation of o2h group and subsequently o2h Ventures.

Yes. O2h group is co-located in Cambridge, UK, and Ahmedabad, India. Its drug discovery platform operates from both locations, and the primary chemistry and biology service capabilities are heavily integrated with the Ahmedabad site. A small US presence is also listed in Cambridge, Massachusetts.

Deal flow appears to be generated in large part through the o2h group ecosystem. The internal therapeutics vertical curates and spins out academic IP and novel pre-seed ideas, while the discovery services arm provides a touchpoint with biotech companies that may become investment prospects. The firm also hosts innovation conferences and community events in Cambridge and India.